Advanced search
Publication Cover
Infection and Drug Resistance Volume 14, 2021 - Issue
Submit an article Journal homepage
232
Views
4
CrossRef citations to date
0
Altmetric
Case Series

Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review

Qian Zhou1 Department of Emergency and Trauma Center, The International Medical Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China
,
Hao Wang2 Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China
,
Tianxiang Zhan2 Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China
,
Xiaofeng Yang1 Department of Emergency and Trauma Center, The International Medical Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of China;2 Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of ChinaCorrespondence[email protected]
&
Liang Wen2 Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, People’s Republic of ChinaCorrespondence[email protected]
Pages 1691-1701 | Published online: 05 May 2021

References

  • van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693–1702. doi:10.1016/s0140-6736(12)61186-623141618
  • Barber KE, Ortwine JK, Akins RL. Ceftazidime/avibactam: who says you can’t teach an old drug new tricks? J Pharm Pharm Sci. 2016;19(4):448–464. doi:10.18433/j3x31r28057163
  • Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15(10):1351–1370. doi:10.1517/14656566.2014.91417224766095
  • Shirley M. Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x29671219
  • Samuel S, Edwards NJ, Rojas LJ, et al. Ceftazidime-avibactam for the treatment of post-neurosurgical meningitis caused by a KPC-producing Klebsiella pneumoniae. Open Forum Infect Dis. 2016;3(suppl_1).
  • Yasmin M, Hanrahan J, Marshall S, et al. Using therapeutic drug monitoring to treat KPC-producing Klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam. Open Forum Infect Dis. 2020;7(9):ofaa349. doi:10.1093/ofid/ofaa34932964066
  • Holyk A, Belden V, Lee JJ, et al. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. J Antimicrob Chemother. 2018;73(1):254–256. doi:10.1093/jac/dkx35829040635
  • Gofman N, To K, Whitman M, Garcia-Morales E. Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin. Am J Health-Syst Pharm. 2018;75(13):953–957. doi:10.2146/ajhp17063229941534
  • Xipell M, Bodro M, Marco F, Losno RA, Cardozo C, Soriano A. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2017;49(2):266–268. doi:10.1016/j.ijantimicag.2016.11.00527979500
  • Rodríguez-Núñez O, Ripa M, Morata L, et al. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018;15:136–139. doi:10.1016/j.jgar.2018.07.01030036695
  • Lauretti L, D’Alessandris QG, Fantoni M, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg. 2017;127(2):370–373. doi:10.3171/2016.6.jns1635227540902
  • Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America’s Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis. 2017;64(6):e34–e65. doi:10.1093/cid/ciw86128203777
  • Gaibani P, Lewis RE, Volpe SL, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017;65:1–3. doi:10.1016/j.ijid.2017.09.01728951106
  • Mikhail S, Singh NB, Kebriaei R, et al. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(8). doi:10.1128/aac.00779-19
  • Chen T, Xu W, Yu K, et al. In vitro activity of ceftazidime-avibactam alone and in combination with amikacin against colistin-Resistant Gram-negative pathogens. Microb Drug Resist. 2020. doi:10.1089/mdr.2019.0463
  • Almarzoky Abuhussain SS, Kuti JL, Nicolau DP. Antibacterial activity of human simulated epithelial lining fluid concentrations of ceftazidime-avibactam alone or in combination with amikacin inhale (BAY41-6551) against carbapenem-resistant pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018;62(7). doi:10.1128/aac.00113-18

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.